Participant screening was initially conducted by phone interview, which assessed alcohol use/dependence, use/dependence of other drugs, medical history, and mental-health history. Participants who met all inclusion criteria and no medical or substance-related exclusion criteria were invited to complete a total of 4 sessions that included clinical, neuropsychological, electrophysiological, and neuroimaging assessments. All participants were informed of the study’s procedures and signed a consent form before their participation. The participants were asked to abstain from using alcohol for at least 24 hours before any lab visits, and a Breathalyzer test was administered to all subjects before each session. Subjects who completed testing were paid for time and travel and, those who completed the entire study, were also given a completion bonus.
